Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
Lists
Only you see this
Abstract
No efficacy or safety differences were found when the approved EOW dosage of agalsidase alfa was increased to weekly administration. Exploratory analyses for 0.4 mg/kg weekly showed similar results.
BibTeX
@inproceedings{golan2015evaluation,
author = {Lubor Goláň and Özlem Göker-Alpan and Myrl Holida and Ikka Kantola and Mariusz Kłopotowski and Johanna Kuusisto and Aleš Linhart and Jacek Musiał and Kathy Nicholls and Derlis Gonzalez Rodríguez and Reena Sharma and Bojan Vujkovac and Peter Chang and Anna Wijatyk},
title = {{Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease}},
booktitle = {Drug},
year = {2015},
doi = {10.2147/dddt.s80928},
}Loading related content...